Cargando…

Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial Carcinomas

It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA‐damaging agents including cisplatin and doxorubicin. Overexpression of mdm2 oncoprotein, a negative regulator of p53, is assumed to be an alternative to p53 dys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakehi, Yoshiyuki, Özdemir, Enver, Habuchi, Tomonori, Yamabe, Hirohiko, Hashimura, Takayuki, Katsura, Yoshitaka, Yoshida, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1998
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921759/ https://www.ncbi.nlm.nih.gov/pubmed/9548450 http://dx.doi.org/10.1111/j.1349-7006.1998.tb00551.x

Ejemplares similares

Immunocytochemical Detection of p53 in Cultures of Exfoliated Cells from Urine of Patients with Urothelial Cancers
por: Okuno, Hiroshi, et al.
Publicado: (1996)

A High Prevalence of Functional Inactivation by Methylation Modification of p16(INK4A)/CDKN2/MTS1 Gene in Primary Urothelial Cancers
por: Akao, Toshiya, et al.
Publicado: (1997)

Allelic Imbalances on Chromosome 20 in Human Transitional Cell Carcinoma
por: Higashi, Shin, et al.
Publicado: (2000)

Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers
por: Wu, Wen‐Jeng, et al.
Publicado: (1995)

Contribution of Chromosome 9p21‐22 Deletion to the Progression of Human Renal Cell Carcinoma
por: Kinoshita, Hidefumi, et al.
Publicado: (1995)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder
por: Okazoe, Homare, et al.
Publicado: (2013)

A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study
por: Inoue, Takamitsu, et al.
Publicado: (2018)

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Cancer Antigen 15-3 Serum Level as a Biomarker for Advanced Micropapillary Urothelial Carcinoma of the Bladder: A Case Report
por: Takayama, Koichiro, et al.
Publicado: (2021)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Neoadjuvant chemotherapy for upper tract urothelial carcinoma
por: Kim, Do Kyung, et al.
Publicado: (2020)

Response of the Urothelial Carcinoma Cell Lines to Cisplatin
por: Holíčková, Andrea, et al.
Publicado: (2022)

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
por: Kurobe, Masahiro, et al.
Publicado: (2016)

Effects of Retinoids and Inhibitors of Arachidonic Acid Metabolism on Tumor‐promoter‐induced Soft Agar Colony Formation of Mouse Epidermal Cells and Rat Urinary Bladder Cells
por: Kanamaru, Hiroshi, et al.
Publicado: (1988)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
por: Suzuki, Kosuke, et al.
Publicado: (2021)

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
por: Baras, Alexander S., et al.
Publicado: (2016)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

In vitro antagonism between cisplatin and vinca alkaloids.
por: Lee, K., et al.
Publicado: (1989)

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
por: Okuyama, Yoshiharu, et al.
Publicado: (2021)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
por: Murakami, Tetsushi, et al.
Publicado: (2021)

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
por: Fosså, S. D., et al.
Publicado: (1996)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
por: Berning, Lena, et al.
Publicado: (2021)

MCM10 overexpression implicates adverse prognosis in urothelial carcinoma
por: Li, Wei-Ming, et al.
Publicado: (2016)

Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma
por: Zhang, Heng, et al.
Publicado: (2017)

SERPINE2 Overexpression Is Associated with Poor Prognosis of Urothelial Carcinoma
por: Chuang, Hao-Wen, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer
por: D’Andrea, David, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
por: Raggi, Daniele, et al.
Publicado: (2021)

Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003)
por: Sugimura, Keijiro, et al.
Publicado: (2020)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
por: Pattarawat, Pawat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_44i082r321d4coqp58o6kv8l35